4.6 Article

Nighttime Insomnia Symptoms and Perceived Health in the America Insomnia Survey (AIS)

Journal

SLEEP
Volume 34, Issue 8, Pages 997-1011

Publisher

OXFORD UNIV PRESS INC
DOI: 10.5665/SLEEP.1150

Keywords

Insomnia; subtypes; comorbidity; perceived health; prevalence; societal burden

Funding

  1. Sanofi-Aventis
  2. Pfizer
  3. Merck Co.
  4. Somaxon
  5. Evotec
  6. Actelion
  7. Vanda
  8. Neurogen
  9. Ventus
  10. Respironics
  11. Jazz Pharmaceuticals
  12. Astra-Zeneca
  13. Daimler Benz
  14. GlaxoSmithKline
  15. Lundbeck
  16. Takeda
  17. UCB
  18. Volkswagen
  19. Weinmann
  20. Sanofi Aventis
  21. Shire Development Inc.
  22. Janssen Pharmceutica
  23. Cephalon
  24. Glaxo Smith Kline
  25. Merck
  26. Neurocrine
  27. Sanofi
  28. Schering-Plough
  29. Sepracor
  30. Syrex
  31. TransOral
  32. Wyeth
  33. Xenoport
  34. Analysis Group Inc.

Ask authors/readers for more resources

Study Objectives: To explore the distribution of the 4 cardinal nighttime symptoms of insomnia-difficulty initiating sleep (DIS), difficulty maintaining sleep (DMS), early morning awakening (EMA), and nonrestorative sleep (NRS)-in a national sample of health plan members and the associations of these nighttime symptoms with sociodemographics, comorbidity, and perceived health. Design/Setting/Participants: Cross-sectional telephone survey of 6,791 adult respondents. Intervention: None. Measurements/Results: Current insomnia was assessed using the Brief Insomnia Questionnaire (BIQ)-a fully structured validated scale generating diagnoses of insomnia using DSM-IV-TR, ICD-10, and RDC/ICSD-2 inclusion criteria. DMS (61.0%) and EMA (52.2%) were more prevalent than DIS (37.7%) and NRS(25.2%) among respondents with insomnia. Sociodemorgraphic correlates varied significantly across the 4 symptoms. All 4 nighttime symptoms were significantly related to a wide range of comorbid physical and mental conditions. All 4 also significantly predicted decrements in perceived health both in the total sample and among respondents with insomnia after adjusting for comorbid physical and mental conditions. Joint associations of the 4 symptoms predicting perceived health were additive and related to daytime distress/impairment. Individual-level associations were strongest for NRS. At the societal level, though, where both prevalence and strength of individual-level associations were taken into consideration, DMS had the strongest associations. Conclusions: The extent to which nighttime insomnia symptoms are stable over time requires future long-term longitudinal study. Within the context of this limitation, the results suggest that core nighttime symptoms are associated with different patterns of risk and perceived health and that symptom-based subtyping might have value.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available